USS Investment Management Ltd Boosts Holdings in Stryker Corporation $SYK

USS Investment Management Ltd increased its position in Stryker Corporation (NYSE:SYK) by 6.5% in the 1st quarter, Holdings Channel.com reports. The firm owned 64,286 shares of the medical technology company’s stock after buying an additional 3,929 shares during the quarter. USS Investment Management Ltd’s holdings in Stryker were worth $21,120,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in SYK. Vanguard Group Inc. lifted its holdings in Stryker by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 33,907,291 shares of the medical technology company’s stock worth $11,917,396,000 after buying an additional 133,892 shares in the last quarter. State Street Corp grew its stake in shares of Stryker by 2.1% during the fourth quarter. State Street Corp now owns 15,254,407 shares of the medical technology company’s stock valued at $5,374,731,000 after acquiring an additional 311,507 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Stryker by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 7,535,572 shares of the medical technology company’s stock valued at $2,636,238,000 after acquiring an additional 69,851 shares in the last quarter. Wellington Management Group LLP increased its position in shares of Stryker by 22.6% during the fourth quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock worth $2,282,192,000 after acquiring an additional 1,198,665 shares during the last quarter. Finally, Alliancebernstein L.P. increased its position in shares of Stryker by 13.3% during the third quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock worth $2,342,987,000 after acquiring an additional 741,542 shares during the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 310,000 shares of the business’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the transaction, the director owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. The trade was a 13.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Robert S. Fletcher sold 4,544 shares of the company’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the transaction, the vice president owned 10,582 shares of the company’s stock, valued at $3,247,298.34. This represents a 30.04% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 323,264 shares of company stock worth $100,659,489. 4.60% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on SYK shares. Sanford C. Bernstein set a $410.00 price target on Stryker in a report on Friday, May 1st. Canaccord Genuity Group dropped their price objective on Stryker from $435.00 to $400.00 and set a “buy” rating on the stock in a report on Friday, May 1st. Needham & Company LLC cut their target price on Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. Leerink Partners reduced their target price on Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a research note on Friday, June 5th. Finally, Robert W. Baird set a $385.00 price target on shares of Stryker in a research report on Friday, May 1st. Sixteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, Stryker has an average rating of “Moderate Buy” and an average target price of $395.33.

Stryker Stock Performance

Shares of SYK stock opened at $314.81 on Wednesday. The company has a market cap of $120.69 billion, a P/E ratio of 36.44, a PEG ratio of 2.12 and a beta of 0.78. The business has a 50 day moving average of $310.38 and a two-hundred day moving average of $339.43. Stryker Corporation has a 52 week low of $281.00 and a 52 week high of $404.87. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The company had revenue of $6.02 billion for the quarter, compared to analyst estimates of $6.34 billion. During the same quarter in the previous year, the company posted $2.84 earnings per share. The firm’s revenue for the quarter was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, analysts anticipate that Stryker Corporation will post 14.98 EPS for the current year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date is Tuesday, June 30th. Stryker’s dividend payout ratio (DPR) is presently 40.74%.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.